Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269267 · ClinicalTrials.gov registry record · Phase 2
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT02269267 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 173 participants.
The verdict
NCT02269267, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
Interventions
- DRUG Imatinib (Stopping their TKI)
- DRUG Dasatinib (Stopping their TKI)
- DRUG Nilotinib (Stopping their TKI)
- DRUG Bosutinib (Stopping their TKI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269267
The ClinicalTrials.gov registry entry for NCT02269267 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Imatinib (Stopping their TKI) is the first listed.
NCT02269267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02269267 about?
NCT02269267 is a clinical study titled "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)". This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
What is the current status of trial NCT02269267?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2014-12-18. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT02269267?
The interventions under investigation include: Imatinib (Stopping their TKI) (DRUG), Dasatinib (Stopping their TKI) (DRUG), Nilotinib (Stopping their TKI) (DRUG), Bosutinib (Stopping their TKI) (DRUG).
Who is sponsoring clinical trial NCT02269267?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.